

Pre-IMPAKT Training Course
Preliminary programme - February 2013

Wednesday, 1 May 2013

11:00-13:00 120'	Pathology for pathologists (I)	Moderator: Giuseppe Viale	HALL 300
20'	How to avoid false positive and false negative results in the assessment of estrogen and progesterone receptor status	Fraser Symmans	
15'	Practical session	Fraser Symmans, Jorge Reis-Filho (discussants)	
20'	How to assess HER2 status revisited	Giuseppe Viale	
15'	Practical session	Giuseppe Viale, Jorge Reis-Filho (discussants)	
20'	How to count and what to count for Ki67	Carsten Denkert	
15'	Practical session	Carsten Denkert, Jorge Reis-Filho (discussants)	
15'	Who takes advantage from central pathology review in clinical trials?	Giuseppe Viale	

13:00-14:00 60'	Introductory briefing over lunch (all)	Chairs and speakers Andrew Tutt, Peter Dubsy, Giuseppe Viale, Christine Desmedt	THE ARC FOYER
---------------------------	---	---	----------------------

14:00-15:15 75'	Pathology for pathologists (II)	Moderators: Giuseppe Viale	HALL 300
20'	How to quantify immune infiltration and tumor cellularity	Carsten Denkert	
15'	Practical session	Carsten Denkert, Jorge Reis-Filho (discussants)	
20'	How to assess the residual tumor burden after neo-adjuvant chemotherapy?	Fraser Symmans	
20'	Practical session	Fraser Symmans, Jorge Reis-Filho (discussants)	

14:00-15:15 75'	Pathology for non-pathologists	Moderator: Christine Desmedt/ Nick Turner	THE ARC ROOM
20'	The role of the pathologist in translational and clinical research	Fraser Symmans	
5'	Q&A		
20'	The standard package from the pathology department (all we can do we H&E slides, advantages and dangers of IHC/FISH markers, etc...)	Giuseppe Viale	
5'	Q&A		
20'	The definition and biological/clinical relevance of the different histological subtypes of breast cancer	Carsten Denkert	
5'	Q&A		

15:15-16:00	Coffee break
--------------------	---------------------

Wednesday, 1 May 2013, cont.

16:00-17:30 90'	Plenary session: Molecular techniques	Co-Chairs: TBC	THE ARC ROOM
15'	Gene expression and CGH	Christine Desmedt	
5'	Q&A		
20'	The ABC of Next Generation Sequencing	Diether Lambrechts	
5'	Q&A		
20'	The main steps in the analysis of NGS data	Manasa Ramakrishna	
5'	Q&A		
15'	Integration of NGS technologies in the clinic	Lucy Yates	
5'	Q&A		

17:30-18:00	Cocktail
--------------------	-----------------

Thursday, 2 May 2013

08:30-10:00 90'	Plenary session: Basic science for dummies	Moderators: Nick Turner and Christine Desmedt	THE ARC ROOM
15'	Important signalling pathways in cancer	Martin Filipits	
5'	Q&A		
15'	Cancer immunity	Karen Willard-Gallo	
5'	Q&A		
20'	Mice models: Why and how?	Cedric Blanpain	
5'	Q&A		
20'	The ENCODE project decoded	Jorge Reis-Filho	
5'	Q&A		

10:00-10:30	Coffee break
--------------------	---------------------

10:30-11:45 75'	Tips for good translational and clinical research	Moderators: Alastair Thompson, Andrew Tutt	THE ARC ROOM
15'	Good samples, the start of good cancer research	Fraser Symmans	
5'	Q&A		
15'	Target identification, validation and early phase clinical trial	Nick Turner	
5'	Q&A		
15'	Modern clinical trials: What does the sponsor want from you?	Cristian Massacesi	
5'	Q&A		
15'	The role of surgeons in translational and clinical research	Alastair Thompson	
	Closing of the pre-IMPAKT training course	Giuseppe Viale and Christine Desmedt	

IMPAKT 2013 CONFERENCE

Working Programme – February 2013

Thursday, 2 May 2013

10:00-11:30	Industry Satellite (TBC)		TBC
11:30-12:00	Lunch for Satellite attendees		TBC
12.00-13:00 60'	Official Welcome & Keynote presentation	Moderator: Martine Piccart	GOLD HALL
10'	Welcome - including short program overview and main themes of IMPAKT 2013	Martine Piccart, Peter Dubsy and Andrew Tutt	
40'	Keynote presentation: Integrating breast cancer genomics and proteomics - shooting for the moon"	Gordon Mills	
10'	Q&A		
13.00-14:00 60'	Heterogeneity in breast cancer captured by DNA and RNA sequencing: What does it mean to clinician and patient?	Moderators: Larry Norton and Jorge Reis-Filho	GOLD HALL
20'	The Cancer Genome Atlas (TCGA) comprehensive molecular portraits of breast cancer	Charles Perou	
20'	METABRIC consortium 2000 Breast Cancer Study: An update	Carlos Caldas	
20'	Moderated audience discussion: What does it mean to clinician and patient?	Larry Norton and Jorge Reis-Filho	
14:00-14:15	Break		FOYERS
14.15-15:15 60'	Industry Satellite: ROCHE		TBC
	TBC		
15:15-16:45 90'	Heterogeneity of breast cancer: How much is there at the start and how much happens over time	Moderators: Charlie Swanton and Angelo Di Leo	GOLD HALL
15'	A historical perspective of intratumor heterogeneity in breast cancer	Charlie Swanton	
15'	Single cell sequencing techniques in early and late breast cancer	Nick Navin	
15'	How do we understand cancer's genomic heterogeneity at different distant sites?	Peter Campbell	
15'	Discussion of heterogeneity from the aspect of tumor evolution and new approaches to clinical trials	Robert A. Gatenby	
7'	Abstract 40O: Contribution of analytical, pre-analytical and intra-tumoral heterogeneity to variance in gene expression measurements from human breast cancers	Rosanna Lau	
7'	Abstract 41O: Heterogeneity of genomic signatures in breast cancer core biopsy	M. Jarzab	
11'	Discussant	Jorge Reis-Filho	
15'	General Q&A		
16:55-17:15	Coffee break		FOYERS

Thursday, 2 May 2013, cont.

17:15-18:45 90'	Can host immune response beat tumor heterogeneity or does it complicate outcomes?	Moderators: Achim Rody and Veronika Sexl	GOLD HALL
20'	The breast cancer Immune stromal interface: Can the lab tell us who is at the meeting and what is the conversation?	Veronika Sexl	
5'	Q&A for PPT 1		
20'	Is there evidence from the clinic that the immune system influences outcomes in breast cancer?	Sherene Loi	
5'	Q&A for PPT 2		
20'	How should immunobiologists and clinical researchers develop immunotherapeutic and biomarker strategies for breast cancer?	Discussion led by Achim Rody and Veronika Sexl	
7'	Abstract 84O: CXCL13-producing follicular helper CD4+ T Cells in extensively-infiltrated breast cancer signal an organized immune response and predict survival	Karen Willard-Gallo	
5'	Abstract Discussion	Giuseppe Curigliano	
8'	General Q&A		

18:45-19:30	Welcome Reception	FOYERS
--------------------	--------------------------	---------------

Friday, 3 May 2013

08:30-9:00 30'	Keynote lecture	Moderator: TBC	GOLD HALL
	Targeting the PI3K/AKT/mTOR axes in breast cancer: A new dawn?	Maurizio Scaltriti	

09:00-10:25 85'	PI3K/AKT/mTOR: Targets/trials and biomarkers. An horizon scan and debate	Moderators: Fabrice André and TBC	GOLD HALL
20'	PI3K alpha specific or general inhibitors	Dejan Juric	
20'	Biomarker analyses in emerging data from PI3K/AKT/mTOR program clinical trials	Ana Vivancos	
7'	Abstract 56O: Predictive value of AKT/mTOR pathway immunohistochemical (IHC) biomarkers for response to preoperative trastuzumab (T) vs trastuzumab + everolimus (T+E) in patients (pts) with early breast cancer (BC): Unicancer RADHER trial results	Mario Campone	
7'	Abstract 42O: Assessment of Genetic Alterations in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer From the BOLERO-2 Trial by Next-Generation Sequencing	Martine Piccart	
20'	Moderated panel discussion: How to optimize patient selection, patient settings (early or late) and target inhibition combinations in PI3K/AKT/mTOR trial design	Ana Vivancos and Cristian Massacesi	
11'	General Q&A		

10:25-10:45	Break	FOYERS
--------------------	--------------	---------------

Friday, 3 May 2013, cont.

10:45-12:15 90'	General Best Abstract Session	Moderator(s): TBC	GOLD HALL
7'	Abstract 530: Predicting risk for late metastasis: The PAM50 risk of recurrence (ROR) score after 5 years of endocrine therapy in postmenopausal women with HR+ early breast cancer: A study on 1,478 patients from the ABCSG-8 trial	Michael Gnant	
3'	Q&A from audience		
7'	Abstract 540: Comparison of five different scores for the prediction of late recurrence for oestrogen receptor positive breast cancer	Ivana Sestak	
3'	Q&A from audience		
7'	Abstract 550: Prognostic and predictive value of IHC4 and ERb1 in the Intergroup Exemestane Study (IES) - On behalf of the PathIES Investigators	Giuseppe Viale	
3'	Q&A from audience		
10'	Discussant 1, PPTs 1,2 and 3	TBC	
5'	Q&A		
7'	Abstract 890: Use of live in-vivo lymphatic imaging techniques to study the effects of immune cell interactions in a syngeneic mouse model of breast cancer.	Sheeba Irshad	
3'	Q&A from audience		
7'	Abstract 900: GE226: a molecular targeted PET imaging agent to assess HER2 status in vivo	Susan Hoppman	
3'	Q&A from audience		
7'	Abstract 910: Early effect of PI3K-Akt-mTOR blockade on in vitro 18F-FDG uptake in HER2+ breast cancer resistant to trastuzumab	Yanina Dockx	
3'	Q&A from audience		
10'	Discussant 2, PPTs 4,5 and 6	Peter Brader	
5'	Q&A		
12:15-13:15	Satellite Symposium		TBC
	TBC		
13:15-13:45	Lunch		FOYERS
13:45-15:15	Industry Satellite Symposium Agendia, Genomic Health, Nanostring and Sividon	Chair: Martine Piccart Co-Chair: Sherene Loi	TBC
	TBC		
15:15-16:35 80'	Single target drug induced cancer rewiring: Is it a problem and can we predict and inhibit cancer reprogramming in the clinic?	Moderators: David Cameron and Neal Rosen	GOLD HALL
15'	What have we learnt from the model systems?	Gary Johnson	
5'	Q&A		
15'	What is the evidence that this is a wider problem we need to address in the clinic?	Neal Rosen	
5'	Q&A		
15'	How do we design trials that improve outcome?	Lisa Carey	
5'	Q&A		
20'	Moderator panel and audience discussion	David Cameron, Neal Rosen and Lisa Carey	
16:35-17:30	Tea and Poster Walk		FOYERS

Friday, 3 May 2013, cont.

17:30-18:30 60'	Dissemination and organ specific metastasis of breast cancer: How does heterogeneity play a role?	Moderators: Michael Gnant and Roger Gomis	GOLD HALL
15'	Extracellular matrix proteins of stem cell niches promote breast cancer metastasis	Thordur Oskarsson	
15'	Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content.	Salvatore Pece	
15'	How do clinicians target the host at metastatic sites?	Michael Gnant	
15'	Moderated audience discussion	Roger Gomis	

Saturday, 4 May 2013

08:30-09:00	Design of biomarker driven neoadjuvant trials	Moderators: Gunter von Minckwitz and Sibylle Loibl	GOLD HALL
20'	Design of biomarker driven neoadjuvant trials	Sibylle Loibl	
10'	Q&A	Gunter von Minckwitz	

9:00 -10:30 90'	Can heterogeneity in advanced breast cancer be captured by molecular imaging?	Moderators: Gary Cook and Peter Brader	GOLD HALL
20'	Novel molecular imaging of drug targets such as HER2 , ER and VEGF	Elisabeth de Vries	
20'	Monitoring bone disease FDG, fluoride and diffusion weighted MRI	Gary Cook	
20'	Advanced MRI in breast cancer	Katja Pinker-Domenig	
7'	TBC		
20'	General Q&A		

10:30-11:00	Coffee break		FOYERS
--------------------	---------------------	--	---------------

11:00-11:30	Award Session - Susan G. Komen for the Cure related	Moderators: TBC	GOLD HALL

11:30-13:00 90'	Debate: In a world of BC heterogeneity is the biopsy of metastasis helpful or distracting?	Moderators: Jonas Bergh and Angelo Di Leo	GOLD HALL
5'	Audience vote		
20'	A) Clinician view pro	Alastair Thompson	
20'	Aa) Biology view con	Charlie Swanton	
20'	B) Clinician view con	Fabrice André	
20'	Bb) Biology view pro	Peter Campbell	
5'	Audience vote		

13:00-13:30	Closing remarks	Moderators: Andrew Tutt and Peter Dubsy	GOLD HALL
--------------------	------------------------	---	------------------